Who are Chloroprocaine HCl 2%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plain bupivacaine, TAC alternate gel, Phrenic nerve block with Ropivacaine, Lidocaine Hydrochloride Preservative Free, Xylocaine with Epinephrine, Tegretol®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chloroprocaine-hcl-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Chloroprocaine HCl 2% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chloroprocaine HCl 2% (Chloroprocaine HCl 2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (ester). Area: Anesthesia.

phase 3 Local anesthetic (ester) Voltage-gated sodium channels Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Chloroprocaine HCl 2% (Chloroprocaine HCl 2%) — Sintetica SA. Chloroprocaine HCl is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Chloroprocaine HCl 2% TARGET	Chloroprocaine HCl 2%	Sintetica SA	phase 3	Local anesthetic (ester)	Voltage-gated sodium channels
Plain bupivacaine	Plain bupivacaine	Fayoum University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
TAC alternate gel	TAC alternate gel	The University of Texas Health Science Center, Houston	marketed	Topical local anesthetic	Voltage-gated sodium channels
Phrenic nerve block with Ropivacaine	Phrenic nerve block with Ropivacaine	Odense University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Lidocaine Hydrochloride Preservative Free	Lidocaine Hydrochloride	Pfizer Inc.	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels (Nav)
Xylocaine with Epinephrine	Xylocaine with Epinephrine	Vrije Universiteit Brussel	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors
Tegretol®	Tegretol®	University of Malaya	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (ester) class)

Sintetica SA · 4 drugs in this class
Centre Hospitalier Universitaire Saint Pierre · 1 drug in this class
Nova Scotia Health Authority · 1 drug in this class
American Genomics, LLC · 1 drug in this class
University of Miami · 1 drug in this class
Wenzhou Medical University · 1 drug in this class
Oregon Health and Science University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Chloroprocaine HCl 2% — Competitive Intelligence Brief. https://druglandscape.com/ci/chloroprocaine-hcl-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab